Industry Insights

  1. Built To Fail: How Today’s Manufacturing Options Leave Pharma At Risk
    6/22/2016

    When planning for the development of a new product, a pharmaceutical manufacturer must determine very early in the process what a product’s anticipated demand will be at the time of launch. Not only is this very difficult to do, but also the consequences of incorrect forecasts can be very costly in a number of ways. Without the ability to predict capacity needs with 100% accuracy, pharma must come up with an effective way to eliminate demand risks.

  2. Recent Research On The Issue Of Bacterial Endotoxins
    2/3/2016

    Bacterial endotoxins are the most common pyrogens found in pharmaceutical products. These substances are found in the outer membrane of Gram-negative bacteria.

  3. Creating A Future Lab Within An Aging Infrastructure
    4/5/2017

    How do you engage a client in a way that frees his/her mind to the prospects of an open flexible lab design? How do you lead them to see the potential within an old, tired building? Many of our clients, life sciences and otherwise, have antiquated labs in antiquated buildings on campuses that have been built to their limits. 

  4. Selecting The Optimal Resins For Mammalian Virus Process Purification And Clearance
    6/28/2016

    The success of biologics for use in humans depends on the ability to effectively remove any viral contaminants. Viral Clearance from biologics is critical to their performance since they can directly infect mammalian cells and cause diseases such as AIDS, mumps, measles, herpes, hepatitis, meningitis, and shingles. And, conversely, studying these disease causing viruses can aid in the development of preventive and curative therapeutics. In this article, Bio-Rad provides snapshots of the different apatite-based media that can be effectively utilized for the process-scale purification of small to mid-sized viruses.

  5. Avoid the Do-Over: Why Early Investment in a Scalable Manufacturing Process is Critical
    8/13/2017

    The road to take a drug compound from discovery to commercialization is long, expensive and often fraught with unforeseen challenges. While every project will undoubtedly face some bumps along its path, far too many programs hit insurmountable obstacles that require innovators to backtrack and correct their course before proceeding, further extending timelines and adding costs.

  6. Ensuring The Greatest Return From Your Poorly Soluble Molecule
    9/5/2016

    The sheer number of potential strategies for improving the solubility of a compound can overwhelm many developers, leaving them unsure how to choose a path forward.

  7. An Efficient Purification Platform For Recombinant Proteins
    2/28/2017

    Mixed-mode chromatography matrices are designed to present multiple interaction modes to resolve target proteins and impurities, entities that are themselves complex multimodal molecules. 

  8. The Standardization Of Single-Use Components For Bioprocessing
    1/20/2016

    As single-use systems become more widely adopted, the focus in the bioprocessing industry is shifting from acceptance of the technology to standardization. 

  9. Autologous Cell Therapies At Crossroads With FDA: What Can You Do To Help?
    7/25/2017

    Regulatory controls on local collection and processing of autologous cells present a major challenge to clinics that want to provide individualized therapies onsite. What does the pharmaceutical industry need to know — and, more importantly, do — to overcome it?

  10. Simplifying Recombinant Protein Production
    12/2/2016

    Biologic drugs have great promise, but they are complex and, as a result, are very expensive to manufacture and subject to technical pitfalls.